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Expression of the CD38 antigen on the surface of chronic lymphocytic leukaemia cells is associated with poor prognosis. [1] [2] [3] Despite the assertion that CD38 is a signalling molecule that transduces activation/differentiation signals in chronic lymphocytic leukaemia (CLL), 4 no clear biological rationale for this correlation has yet emerged. Several confounding factors prevent easy dissection of the role of CD38 in the pathogenesis of CLL.
Firstly, CD38 appears to be differentially expressed in the lymph nodes, bone marrow and peripheral blood and may be modulated by microenvironmental factors. 5, 6 Secondly, CD38 expression in CLL is frequently coincident with other important poor prognostic markers including high ZAP-70 and unmutated V H genes when using categorical cutoff levels to define the patient cohort. 7 Therefore, the nature and precise contribution of CD38 expression to inferior outcome cannot readily be evaluated unless a more systematic approach is employed.
To this end, we analysed peripheral blood samples derived from CLL patients with bimodal expression of the CD38 antigen in order to determine whether these phenotypically distinct subclonal populations had different patterns of ZAP-70 expression (n ¼ 36). Remarkably, CD38
þ CLL cells showed consistently higher levels of ZAP-70 expression when compared to their CD38 À counter-parts ( Figure 1 ). This was independent of the size of the CD38 þ subclonal population or the overall 
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Figure 2
Cell sorted CD38 þ subclonal populations of chronic lymphocytic leukaemia cells have constitutively higher levels of global tyrosine phosphorylation, as measured by flow cytometry, and a differential capacity to signal via the B-cell receptor following stimulation with anti-IgM when compared with their CD38
À counterparts derived from the same patient.
Letters to the Editor ZAP-70 status of the patient, that is, o or X20% positive. Indeed, the CD38 þ CLL cells demonstrated equivalent ZAP-70 expression to their corresponding T cells in all the samples tested, even in samples categorized as ZAP-70 negative (o20% positive).
We next physically cell sorted CD38 þ and CD38 À subclonal populations from the same patient (n ¼ 10), in order to establish whether these cells had a differential response to B-cell receptor stimulation. The CD38 þ CLL cells showed constitutively higher basal tyrosine phosphorylation when compared with their CD38 À counter parts. They also demonstrated a differential capacity to signal following stimulation with anti-IgM (Figure 2 ). Given that we have already established that CD38 þ CLL cells express higher levels of ZAP-70, a molecule known to enhance BCR signalling, 8 it seems likely that CD38 and ZAP-70 play complementary roles in the basal activation and signalling capacity of CLL cells. Importantly, our findings provide a biological rationale for the work of Ghia et al., 5 who demonstrated that CD38 expression, regardless of the size of the clone, confers poor prognosis in CLL. The most frequent cause of treatment failure after allogeneic stem cell transplantation (SCT) for leukemia is relapse of the underlying host leukemia. However, rare cases have been reported in which cytogenetic analysis, alone or in combination with molecular analysis, has indicated that the new leukemia originated in the donor cells. 1 Donor cell leukemia (DCL) is a rare event of unknown incidence after allogeneic SCT.
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We report a patient with acute myeloid leukemia (AML) (FAB M0) who developed an AML (FAB M2) in the donor cells 11 months after unrelated cord blood transplantation (CBT). A 32-year-old woman complained of fever having an unknown origin, and she had a diagnosis of AML (FAB M0) (peroxidase staining negative, CD13 þ , CD33 þ , CD34 þ ). Cytogenetic studies showed a chromosomal abnormality with 47, XX, add (10)(p11), À11,?13p, þ mar1 Â 2 (20/20). She achieved complete remission with two courses of remission induction therapies. Three courses of consolidation and three courses of intensification therapies were then given sequentially. Her conditioning regimen consisted of 8 g/m 2 of cytosine arabinoside, 120 mg/kg of cyclophosphamide and 12 Gy of total body irradiation (TBI) divided into six fractions over 3 days, and she received CBT from a two HLA loci-mismatched unrelated female donor. The total number of infused nucleated cells was 2.90 Â 10 7 /kg, CD34 þ cells were 1.74 Â 10 5 /kg, and CFU-GM were 2.56 Â 10 4 /kg. GVHD prophylaxis was 3 mg/kg of cyclosporine A (CsA) and short-term methotrexate. Her peripheral blood leukocyte count reached more than 1.0 Â 10 9 /l on day þ 20 post-CBT. Engraftment of donor cells was confirmed by short tandem repeat (STR) analysis on day þ 26 (data not shown). She had acute GVHD (skin stage 3, Grade II) and bronchiolites obliterans organizing pneumonia. We stopped her regimen to administer steroid and CsA for treatment of GVHD and BOOP on day þ 135 and day þ 191, respectively. Examination of her bone marrow on day þ 241 revealed the presence of 7% atypical early cells. However, STR analysis on day þ 253 showed that these cells were completely of the donor type ( Figure 1) . Therefore, we carried out FACS analysis of her bone marrow cells, and this revealed that the atypical early cells expressed CD10, CD19 and CD20. In addition, STR analysis of the bone marrow cells on day þ 301 also showed that the atypical cells were completely of the donor type (Figure 1 ). At this point in time, we diagnosed hematogone. 2 However, her peripheral blood contained 9% blast cells, and her bone marrow also contained 20% blast cells on day þ 335. As for the character of the blast cells, peroxidase staining was positive and
